drugset / Trial / NCT05464836

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

NCT05464836

Phase 2 Terminated 2 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To learn if the combination of 2 study drugs, CB-103 and venetoclax, can help to control T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL) in adolescent and young adult patients

Timeline

Start
2023-04-06
Primary completion
2024-08-12
Completion
2024-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LIMANTRAFIN Small molecule Oral
Subject Venetoclax Small molecule Oral